## Pedro M D Moreno

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4202486/publications.pdf

Version: 2024-02-01

34 papers 1,054 citations

16 h-index 30 g-index

34 all docs

34 docs citations

times ranked

34

1481 citing authors

#	Article	IF	CITATIONS
1	Toward the therapeutic application of small interfering RNA bioconjugates in the central nervous system., 2020,, 333-374.		O
2	Delivery of Antisense Oligonucleotides Mediated by a Hydrogel System: In Vitro and In Vivo Application in the Context of Spinal Cord Injury. Methods in Molecular Biology, 2019, 2036, 205-219.	0.4	0
3	Hydrogel-Assisted Antisense LNA Gapmer Delivery for In Situ Gene Silencing in Spinal Cord Injury. Molecular Therapy - Nucleic Acids, 2018, 11, 393-406.	2.3	13
4	CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. Nucleic Acids Research, 2017, 45, 5153-5169.	6.5	19
5	Biodegradable PEG–dendritic block copolymers: synthesis and biofunctionality assessment as vectors of siRNA. Journal of Materials Chemistry B, 2017, 5, 4901-4917.	2.9	15
6	Design and preparation of biomimetic and bioinspired materials. , 2017, , 1-44.		3
7	Synthetic m3G-CAP attachment necessitates a minimum trinucleotide constituent to be recognised as a nuclear import signal. RSC Advances, 2016, 6, 51367-51373.	1.7	8
8	Antisense Oligonucleotides Modulating Activation of a Nonsense-Mediated RNA Decay Switch Exon in the ATM Gene. Nucleic Acid Therapeutics, 2016, 26, 392-400.	2.0	9
9	A high-throughput bioimaging study to assess the impact of chitosan-based nanoparticle degradation on DNA delivery performance. Acta Biomaterialia, 2016, 46, 129-140.	4.1	9
10	Delivery of Splice Switching Oligonucleotides by Amphiphilic Chitosan-Based Nanoparticles. Molecular Pharmaceutics, 2016, 13, 344-356.	2.3	14
11	Next-generation bis-locked nucleic acids with stacking linker and 2′-glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes. Nucleic Acids Research, 2016, 44, 2007-2019.	6.5	24
12	A murine model of acute myeloid leukemia withEviloverexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells. Leukemia and Lymphoma, 2016, 57, 183-192.	0.6	1
13	695. Splice-Correction of X-Linked Agammaglobulinemia in a Human BAC-Transgenic Mouse Model Using Oligonucleotides. Molecular Therapy, 2015, 23, S277.	3.7	0
14	RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. Journal of Molecular and Cellular Cardiology, 2015, 82, 186-193.	0.9	19
15	Nuclease resistant oligonucleotides with cell penetrating properties. Chemical Communications, 2015, 51, 4044-4047.	2.2	18
16	Functionalized chitosan derivatives as nonviral vectors: physicochemical properties of acylated N,N,N-trimethyl chitosan/oligonucleotide nanopolyplexes. Soft Matter, 2015, 11, 8113-8125.	1.2	30
17	Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Frontiers in Chemistry, 2014, 2, 87.	1.8	91
18	Repeatable, Inducible Micro-RNA-Based Technology Tightly Controls Liver Transgene Expression. Molecular Therapy - Nucleic Acids, 2014, 3, e172.	2.3	3

#	Article	IF	CITATIONS
19	Translating chitosan to clinical delivery of nucleic acid-based drugs. MRS Bulletin, 2014, 39, 60-70.	1.7	24
20	Design and Application of Bispecific Splice-Switching Oligonucleotides. Nucleic Acid Therapeutics, 2014, 24, 13-24.	2.0	5
21	Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model. Journal of Clinical Investigation, 2014, 124, 4067-4081.	3.9	39
22	Synthesis and evaluation of stability of m3G-CAP analogues in serum-supplemented medium and cytosolic extract. Bioorganic and Medicinal Chemistry, 2013, 21, 7921-7928.	1.4	10
23	Development of bis-locked nucleic acid (bisLNA) oligonucleotides for efficient invasion of supercoiled duplex DNA. Nucleic Acids Research, 2013, 41, 3257-3273.	6.5	25
24	Circular RNA interference effector molecules (WO10084371). Expert Opinion on Therapeutic Patents, 2011, 21, 115-119.	2.4	2
25	Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Research, 2011, 39, 3972-3987.	6.5	262
26	A Peptide-based Vector for Efficient Gene Transfer In Vitro and In Vivo. Molecular Therapy, 2011, 19, 1457-1467.	3.7	94
27	Optimizing anti-gene oligonucleotide â€~Zorro-LNA' for improved strand invasion into duplex DNA. Nucleic Acids Research, 2011, 39, 1142-1154.	6.5	29
28	PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Research, 2011, 39, 5284-5298.	6.5	199
29	Temperature-Assisted Cyclic Hybridization (TACH): An Improved Method for Supercoiled DNA Hybridization. Molecular Biotechnology, 2010, 45, 171-179.	1.3	3
30	A synthetic snRNA m3G-CAP enhances nuclear delivery of exogenous proteins and nucleic acids. Nucleic Acids Research, 2009, 37, 1925-1935.	6.5	29
31	Nanotechnology approaches for gene transfer. Genetica, 2009, 137, 47-56.	0.5	22
32	Fatty acid–spermine conjugates as DNA carriers for nonviral in vivo gene delivery. Gene Therapy, 2009, 16, 1429-1440.	2.3	17
33	Building Biologically Active Nucleic Acid Nanocomplexes. Nucleic Acids Symposium Series, 2008, 52, 27-28.	0.3	1
34	Increased stability and specificity through combined hybridization of peptide nucleic acid (PNA) and locked nucleic acid (LNA) to supercoiled plasmids for PNA-anchored "Bioplex―formation. New Biotechnology, 2005, 22, 185-192.	2.7	17